Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol

Biochemical Journal

Volumn 465, Issue , 2015, Pages 103-114

  Wiek, Constanze ^a   Schmidt, Eva M ^a   Roellecke, Katharina ^a   Freund, Marcel ^a   Nakano, Mariko ^b   Kelly, Edward J ^b   Kaisers, Wolfgang ^a   Yarov Yarovoy, Vladimir ^c   Kramm, Christof M ^d   Rettie, Allan E ^b   Hanenberg, Helmut ^a,e  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

4 ipomeanol; Cytochrome P450 4B1 (CYP4B1); Suicide gene system

Indexed keywords

4 IPOMEANOL; AMINO ACID; CYTOCHROME P450 4B1; MUTANT PROTEIN; 4-IPOMEANOL; CYTOCHROME P-450 CYP4B1; PROLINE; TERPENE; UNSPECIFIC MONOOXYGENASE;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN STABILITY; SUICIDE GENE; T LYMPHOCYTE; ANIMAL; BIOCATALYSIS; CHEMISTRY; DRUG EFFECTS; ENZYME STABILITY; HEK293 CELL LINE; METABOLISM; PROTEIN ENGINEERING; RABBIT; STRUCTURE ACTIVITY RELATION; SUICIDE TRANSGENE;

MAMMALIA; ORYCTOLAGUS CUNICULUS;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOCATALYSIS; ENZYME STABILITY; GENES, TRANSGENIC, SUICIDE; HEK293 CELLS; HEP G2 CELLS; HUMANS; PROLINE; PROTEIN ENGINEERING; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES; TERPENES;

EID: 84918540338     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20140813     Document Type: Article

References (48)

1. Ortiz de Montellano, P. R. and Nelson, S. D. (2011) Rearrangement reactions catalyzed by cytochrome P450s. Arch. Biochem. Biophys. 507, 95-110 CrossRef PubMed
2. Gotoh, O. (2012) Evolution of cytochrome P450 genes from the viewpoint of genome informatics. Biol. Pharm. Bull. 35, 812-817 CrossRef PubMed
3. Lamb, D. C. and Waterman, M. R. (2013) Unusual properties of the cytochrome P450 superfamily. Philos. Trans. R. Soc. Lond. B Biol. Sci. 368, 20120434 CrossRef PubMed
4. Nebert, D. W., Wikvall, K. and Miller, W. L. (2013) Human cytochromes P450 in health and disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 368, 20120431 CrossRef PubMed
5. Munro, A. W., Girvan, H. M., Mason, A. E., Dunford, A. J. and McLean, K. J. (2013) What makes a P450 tick? Trends Biochem. Sci. 38, 140-150 CrossRef PubMed
6. Johnson, E. F. and Stout, C. D. (2013) Structural diversity of eukaryotic membrane cytochrome P450s. J. Biol. Chem. 288, 17082-17090 CrossRef PubMed
7. Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W. et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1-42 CrossRef PubMed
8. Baer, B. R. and Rettie, A. E. (2006) CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism. Drug Metab. Rev. 38, 451-476 CrossRef PubMed
9. Zhang, J. Y., Wang, Y. and Prakash, C. (2006) Xenobiotic-metabolizing enzymes in human lung. Curr. Drug Metab. 7, 939-948 CrossRef PubMed
10. Edson, K. Z. and Rettie, A. E. (2013) CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities. Curr. Top. Med. Chem. 13, 1429-1440 CrossRef PubMed
11. Czerwinski, M., McLemore, T. L., Philpot, R. M., Nhamburo, P. T., Korzekwa, K., Gelboin, H. V. and Gonzalez, F. J. (1991) Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: evidence for species-specific metabolism. Cancer Res. 51, 4636-4638 PubMed
12. Verschoyle, R. D., Philpot, R. M., Wolf, C. R. and Dinsdale, D. (1993) CYP4B1 activates 4-ipomeanol in rat lung. Toxicol. Appl. Pharmacol. 123, 193-198 CrossRef PubMed
13. Rettie, A. E., Sheffels, P. R., Korzekwa, K. R., Gonzalez, F. J., Philpot, R. M. and Baillie, T. A. (1995) CYP4 isozyme specificity and the relationship between ω-hydroxylation and terminal desaturation of valproic acid. Biochemistry 34, 7889-7895 CrossRef PubMed
14. Christian, M. C., Wittes, R. E., Leyland-Jones, B., McLemore, T. L., Smith, A. C., Grieshaber, C. K., Chabner, B. A. and Boyd, M. R. (1989) 4-Ipomeanol: a novel investigational new drug for lung cancer. J. Natl. Cancer Inst. 81, 1133-1145 CrossRef PubMed
15. Hansen, A. A. (1925) Two fatal cases of potato poisoning. Science 61, 340-341 CrossRef PubMed
16. Wilson, B. J., Yang, D. T. and Boyd, M. R. (1970) Toxicity of mould-damaged sweet potatoes (Ipomoea batatas). Nature 227, 521-522 CrossRef PubMed
17. Wilson, B. J., Boyd, M. R., Harris, T. M. and Yang, D. T. (1971) A lung oedema factor from mouldy sweet potatoes (Ipomoea batatas). Nature 231, 52-53 CrossRef PubMed
18. Boyd, M. R. (1976) Role of metabolic activation in the pathogenesis of chemically induced pulmonary disease: mechanism of action of the lung-toxic furan, 4-ipomeanol. Environ. Health Perspect. 16, 127-138 CrossRef PubMed
19. Doster, A. R., Mitchell, F. E., Farrell, R. L. and Wilson, B. J. (1978) Effects of 4-ipomeanol, a product from mold-damaged sweet potatoes, on the bovine lung. Vet. Pathol. 15, 367-375 CrossRef PubMed
20. Baer, B. R., Rettie, A. E. and Henne, K. R. (2005) Bioactivation of 4-ipomeanol by CYP4B1: adduct characterization and evidence for an enedial intermediate. Chem. Res. Toxicol. 18, 855-864 CrossRef PubMed
21. Falzon, M., McMahon, J. B., Schuller, H. M. and Boyd, M. R. (1986) Metabolic activation and cytotoxicity of 4-ipomeanol in human non-small cell lung cancer lines. Cancer Res. 46, 3484-3489 PubMed
22. Rowinsky, E. K., Noe, D. A., Ettinger, D. S., Christian, M. C., Lubejko, B. G., Fishman, E. K., Sartorius, S. E., Boyd, M. R. and Donehower, R. C. (1993) Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. Cancer Res. 53, 1794-1801 PubMed
23. Kasturi, V. K., Dearing, M. P., Piscitelli, S. C., Russell, E. K., Sladek, G. G., O'Neil, K., Turner, G. A., Morton, T. L., Christian, M. C., Johnson, B. E. and Kelley, M. J. (1998) Phase I study of a five-day dose schedule of 4-ipomeanol in patients with non-small cell lung cancer. Clin. Cancer Res. 4, 2095-2102 PubMed
24. Lakhanpal, S., Donehower, R. C. and Rowinsky, E. K. (2001) Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma. Invest. New Drugs 19, 69-76 CrossRef PubMed
25. Zheng, Y. M., Henne, K. R., Charmley, P., Kim, R. B., McCarver, D. G., Cabacungan, E. T., Hines, R. N. and Rettie, A. E. (2003) Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis. Toxicol. Appl. Pharmacol. 186, 119-126 CrossRef PubMed
26. Zheng, Y. M., Fisher, M. B., Yokotani, N., Fujii-Kuriyama, Y. and Rettie, A. E. (1998) Identification of a meander region proline residue critical for heme binding to cytochrome P450: implications for the catalytic function of human CYP4B1. Biochemistry 37, 12847-12851 CrossRef PubMed
27. Imaoka, S., Hayashi, K., Hiroi, T., Yabusaki, Y., Kamataki, T. and Funae, Y. (2001) A transgenic mouse expressing human CYP4B1 in the liver. Biochem. Biophys. Res. Commun. 284, 757-762 CrossRef PubMed
28. Rainov, N. G., Sena-Esteves, M., Fraefel, C., Dobberstein, K. U., Chiocca, E. A. and Breakefield, X. O. (1998) A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. Adv. Exp. Med. Biol. 451, 393-403 CrossRef PubMed
29. Nakano, M., Kelly, E. J., Wiek, C., Hanenberg, H. and Rettie, A. E. (2012) CYP4V2 in Bietti's crystalline dystrophy: ocular localization, metabolism of ω-3 polyunsaturated fatty acids and functional deficit of the p.H331P variant. Mol. Pharmacol. 82, 679-686 CrossRef PubMed
30. Hanenberg, H., Xiao, X. L., Dilloo, D., Hashino, K., Kato, I. and Williams, D. A. (1996) Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2, 876-882 CrossRef PubMed
31. Pollok, K. E., Hanenberg, H., Noblitt, T. W., Schroeder, W. L., Kato, I., Emanuel, D. and Williams, D. A. (1998) High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. J. Virol. 72, 4882-4892 PubMed
32. Hanenberg, H., Hashino, K., Konishi, H., Hock, R. A., Kato, I. and Williams, D. A. (1997) Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells. Hum. Gene Ther. 8, 2193-2206 CrossRef PubMed
33. Chivian, D. and Baker, D. (2006) Homology modeling using parametric alignment ensemble generation with consensus and energy-based model selection. Nucleic Acids Res. 34, e112 CrossRef PubMed
34. Kim, D. E., Chivian, D. and Baker, D. (2004) Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res. 32, W526-W531 CrossRef PubMed
35. Sansen, S., Yano, J. K., Reynald, R. L., Schoch, G. A., Griffin, K. J., Stout, C. D. and Johnson, E. F. (2007) Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J. Biol. Chem. 282, 14348-14355 CrossRef PubMed
36. Lengler, J., Holzmuller, H., Salmons, B., Gunzburg, W. H. and Renner, M. (2005) FMDV-2A sequence and protein arrangement contribute to functionality of CYP2B1-reporter fusion protein. Anal. Biochem. 343, 116-124 CrossRef PubMed
37. Schambach, A., Bohne, J., Baum, C., Hermann, F. G., Egerer, L., von Laer, D. and Giroglou, T. (2006) Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther. 13, 641-645 CrossRef PubMed
38. Parkinson, O. T., Liggitt, H. D., Rettie, A. E. and Kelly, E. J. (2013) Generation and characterization of a Cyp4b1 null mouse and the role of CYP4B1 in the activation and toxicity of ipomeanol. Toxicol. Sci. 134, 243-250 CrossRef PubMed
39. Hasemann, C. A., Kurumbail, R. G., Boddupalli, S. S., Peterson, J. A. and Deisenhofer, J. (1995) Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 3, 41-62 CrossRef PubMed
40. Peterson, J. A. and Graham, S. E. (1998) A close family resemblance: the importance of structure in understanding cytochromes P450. Structure 6, 1079-1085 CrossRef PubMed
41. Krone, N., Riepe, F. G., Grotzinger, J., Partsch, C. J., Bramswig, J. and Sippell, W. G. (2005) The residue E351 is essential for the activity of human 21-hydroxylase: evidence from a naturally occurring novel point mutation compared with artificial mutants generated by single amino acid substitutions. J. Mol. Med. (Berl.) 83, 561-568 CrossRef PubMed
42. Werck-Reichhart, D. and Feyereisen, R. (2000) Cytochromes P450: a success story. Genome Biol. 1, REVIEWS3003 CrossRef PubMed
43. 5 and cytochrome P450 reductase. J. Biol. Chem. 273, 17036-17049 CrossRef PubMed
44. Lehnerer, M., Schulze, J., Achterhold, K., Lewis, D. F. and Hlavica, P. (2000) Identification of key residues in rabbit liver microsomal cytochrome P450 2B4: importance in interactions with NADPH-cytochrome P450 reductase. J. Biochem. 127, 163-169 CrossRef PubMed
45. Imaoka, S., Yoneda, Y., Sugimoto, T., Hiroi, T., Yamamoto, K., Nakatani, T. and Funae, Y. (2000) CYP4B1 is a possible risk factor for bladder cancer in humans. Biochem. Biophys. Res. Commun. 277, 776-780 CrossRef PubMed
46. Correia, M. A., Wang, Y., Kim, S. M. and Guan, S. (2014) Hepatic cytochrome P450 ubiquitination: conformational phosphodegrons for E2/E3 recognition? IUBMB Life 66, 78-88 CrossRef PubMed
47. Frank, S., Steffens, S., Fischer, U., Tlolko, A., Rainov, N. G. and Kramm, C. M. (2002) Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy. Cancer Gene Ther. 9, 178-188 CrossRef PubMed
48. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C. and Ferrin, T. E. (2004) UCSF Chimera: a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 CrossRef PubMed